{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T05:15:54Z","timestamp":1778130954253,"version":"3.51.4"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the association of serum uric acid (SUA) with established lupus nephritis (LN) and to explore its prospective association with incident LN in systemic lupus erythematosus (SLE) patients presenting with preserved renal function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We enrolled 97 SLE patients with preserved renal function (creatinine clearance \u2265 90 mL\/min), including 58 with baseline LN and 39 without LN (NLN). Baseline associations were evaluated using multivariable logistic regression, with a sensitivity model further adjusting for baseline glucocorticoid dose, mycophenolate mofetil use, and cyclophosphamide use. Model discrimination was compared by Area Under the Curve (AUC) and DeLong testing. The baseline NLN cohort was followed for 3 years, and incident LN was analyzed using a Cox model adjusted for baseline Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline SUA was higher in LN than in NLN patients (489.2 \u00b1 80.8 vs. 339.8 \u00b1 104.2 \u00b5mol\/L, p &amp;lt; 0.001). Higher SUA remained associated with baseline LN in the main model (adjusted OR 4.20 per 1-SD increase, 95% CI 2.00\u20138.83, p &amp;lt; 0.001) and after additional adjustment for baseline treatment exposures (adjusted OR 6.32, 95% CI 1.21\u201332.96, p = 0.029). Adding SUA to the base clinical model increased discrimination within this dataset (AUC 0.863 to 0.929; DeLong test p = 0.001). During 3 years of follow-up, 11 NLN patients (28.2%) developed incident LN; in exploratory Cox analysis adjusted for baseline SLEDAI, higher baseline SUA was associated with a possible increased hazard of subsequent LN (adjusted HR 1.83, 95% CI 1.09\u20133.07, p = 0.022).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this dataset, SUA was associated with LN risk stratification in SLE patients with preserved renal function, but this signal may also reflect broader disease activity, systemic inflammation, and treatment-related factors. The renal specificity of SUA remains uncertain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1831052","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T04:57:07Z","timestamp":1778129827000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum uric acid in systemic lupus erythematosus with preserved renal function: a cross-sectional and longitudinal analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaolu","family":"Huang","sequence":"first","affiliation":[{"name":"Rheumatology Department of Zhangzhou Affiliated Hospital of Fujian Medical University","place":["Zhangzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongpu","family":"Chen","sequence":"additional","affiliation":[{"name":"Rheumatology Department of Zhangzhou Affiliated Hospital of Fujian Medical University","place":["Zhangzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulin","family":"Wang","sequence":"additional","affiliation":[{"name":"Rheumatology Department of Zhangzhou Affiliated Hospital of Fujian Medical University","place":["Zhangzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuan","family":"Lin","sequence":"additional","affiliation":[{"name":"Rheumatology Department of Zhangzhou Affiliated Hospital of Fujian Medical University","place":["Zhangzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.5014\/ajot.2017.71s1-po4123","article-title":"Systemic lupus erythematosus: a review","volume":"331","author":"Siegel","year":"2024","journal-title":"Jama"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mnh.0000444816.57378.21","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103404","article-title":"From systemic lupus erythematosus to lupus nephritis: the evolving road to targeted therapies","volume":"22","author":"Xipell","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 Clinical Practice Guideline for the management of lupus nephritis","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.09.002","article-title":"Executive summary of the KDIGO 2024 Clinical Practice Guideline for the management of lupus nephritis","volume":"105","author":"Rovin","year":"2024","journal-title":"Kidney Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ard.2025.09.007","article-title":"EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update","volume":"85","author":"Fanouriakis","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2023.101925","article-title":"Kidney involvement in systemic lupus erythematosus: from the patient assessment to a tailored treatment","volume":"37","author":"Mejia-Vilet","year":"2023","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1053\/j.akdh.2023.11.003","article-title":"A comprehensive and practical approach to the management of lupus nephritis in the current era","volume":"31","author":"Wiegley","year":"2024","journal-title":"Adv Kidney Dis Health"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.15079","article-title":"Population-wide long-term study of incidence, renal failure, and mortality rates for lupus nephritis","volume":"27","author":"Nossent","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/nep.14427","article-title":"Lupus nephritis and chronic kidney disease: a scoping review","volume":"30","author":"Teoh","year":"2025","journal-title":"Nephrol (Carlton)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/life15101497","article-title":"Biomarkers in lupus nephritis: an evidence-based comprehensive review","volume":"15","author":"Vrabie","year":"2025","journal-title":"Life (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/bs.acc.2024.10.002","article-title":"Lupus nephritis: biomarkers","volume":"124","author":"Dobrowolski","year":"2025","journal-title":"Adv Clin Chem"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25020805","article-title":"Lupus nephritis biomarkers: a critical review","volume":"25","author":"Alduraibi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914526","article-title":"Lupus nephritis risk factors and biomarkers: an update","volume":"24","author":"Renaudineau","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/labmed\/lmae015","article-title":"Noninvasive biomarkers for lupus nephritis","volume":"55","author":"Liu","year":"2024","journal-title":"Lab Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1682280","article-title":"Age-stratified risk factors and predictive models for progression to lupus nephritis in patients with systemic lupus erythematosus: a review","volume":"16","author":"Sun","year":"2025","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.11.014","article-title":"Prediction models of treatment response in lupus nephritis","volume":"101","author":"Ayoub","year":"2022","journal-title":"Kidney Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1413569","article-title":"Machine learning models predicts risk of proliferative lupus nephritis","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.889931","article-title":"Identification and validation of a urinary biomarker panel to accurately diagnose and predict response to therapy in lupus nephritis","volume":"13","author":"Whittall-Garcia","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2019121285","article-title":"Urinary soluble CD163: a novel noninvasive biomarker of activity for lupus nephritis","volume":"31","author":"Mejia-Vilet","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1003761","DOI":"10.3389\/fimmu.2022.935700","article-title":"Urine soluble CD163 is a promising biomarker for the diagnosis and evaluation of lupus nephritis","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2023.2236022","article-title":"Analytical validation of urine ALCAM ELISA as a test for lupus nephritis","volume":"23","author":"Lei","year":"2023","journal-title":"Expert Rev Mol Diagn"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-024-06883-x","article-title":"Clinico-serological associations of urinary activated leukocyte cell adhesion molecule in systemic lupus erythematosus and lupus nephritis","volume":"43","author":"Amer","year":"2024","journal-title":"Clin Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae559","article-title":"Soluble urine activated leukocyte cell adhesion molecule is a strong predictor of lupus nephritis","volume":"64","author":"Chu","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14242787","article-title":"Urinary immune complexes reflect renal pathology in lupus nephritis","volume":"14","author":"Tang","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.semnephrol.2004.09.007","article-title":"Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease","volume":"25","author":"Kanellis","year":"2005","journal-title":"Semin Nephrol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"F993","DOI":"10.1152\/ajprenal.00637.2014","article-title":"Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy","volume":"308","author":"Kim","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00560.2012","article-title":"Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease","volume":"304","author":"Ryu","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05473-x","article-title":"Serum uric acid as a sensitive concordant marker with lupus nephritis and new onset of renal damage: a prospective cohort study","volume":"40","author":"Elnady","year":"2021","journal-title":"Clin Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/9781119636540.ch25","article-title":"Association between serum uric acid level and systemic lupus erythematosus kidney outcome","volume":"32","author":"Han","year":"2023","journal-title":"Lupus"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/ar7nsq","article-title":"Elevated serum uric acid is associated with renal arteriolopathy and predict poor outcome in patients with lupus nephritis","volume":"42","author":"Wang","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04620-3","article-title":"Is serum uric acid a predictor of long-term renal outcome in lupus nephritis","volume":"38","author":"Ugolini-Lopes","year":"2019","journal-title":"Clin Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9030773","article-title":"Serum uric acid is associated with renal prognosis of lupus nephritis in women but not in men","volume":"9","author":"Oh","year":"2020","journal-title":"J Clin Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1831052\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T04:57:08Z","timestamp":1778129828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1831052\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2026.1831052"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1831052","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"article-number":"1831052"}}